文献速递瓣膜病与结构性心脏病血脂与心血管预防

外科植入生物主动脉瓣的血流动力学恶化

Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves.
PubMed 文献 · J Am Coll Cardiol · 2018-07-09

前瞻性纵向研究纳入137例外科主动脉生物瓣患者,基线行多普勒超声、CT评估瓣叶钙化及空腹血代谢风险谱,3年后复查超声。18例(13.1%)出现血流动力学瓣膜恶化(HVD),瓣叶钙化和HVD均为复合终点(死亡或再干预)的独立预测因子。Lp-PLA2、PCSK9及胰岛素抵抗与HVD发生相关。

要点

  • CT检出瓣叶钙化是HVD的强预测因子,并增加风险预测能力。
  • HVD独立关联再干预或死亡风险显著升高(HR 5.12)。
  • Lp-PLA2、PCSK9及胰岛素抵抗等代谢异常与HVD发生相关。

核心结论

  • 多普勒超声识别的HVD与外科主动脉生物瓣患者再干预或死亡风险显著增加独立相关。
  • 以Lp-PLA2、PCSK9升高及胰岛素抵抗为特征的代谢异常与HVD风险增加相关。
  • CT检出瓣叶钙化是HVD的强预测因子,提供增量风险预测能力。

研究设计与样本

  • 前瞻性纵向研究,纳入137例外科植入主动脉生物瓣患者,瓣膜植入中位时间6.7年(IQR 5.1–9.1)。
  • 基线行完整多普勒超声、多排CT定量瓣叶钙化及空腹血代谢风险谱评估。
  • 基线后中位3年(IQR 2.9–3.3)复查多普勒超声。

主要发现

  • 瓣叶钙化(HR 2.58;95%CI 1.35–4.82;p=0.005)和HVD(HR 5.12;95%CI 2.57–9.71;p<0.001)为主要终点的独立预测因子。
  • 调整年龄、性别及主动脉瓣置换术后时间后,瓣叶钙化、胰岛素抵抗(HOMA指数≥2.7)、Lp-PLA2活性(每增加0.1 nmol/min/ml)及高PCSK9水平(≥305 ng/ml)与HVD发生相关。

关键数值与推荐

  • HVD定义为平均跨瓣压差年化变化≥3 mmHg/年,和/或跨瓣反流加重≥1/3级。
  • 主要终点为全因死亡或生物瓣失败导致的主动脉再干预(再次外科换瓣或经导管瓣中瓣植入)的非层级复合终点。
  • 胰岛素抵抗定义为HOMA指数≥2.7;高PCSK9定义为≥305 ng/ml。

临床怎么用

  • 对外科主动脉生物瓣患者,应关注代谢异常(Lp-PLA2、PCSK9、胰岛素抵抗)以识别HVD高危者。
  • CT检出瓣叶钙化可用于风险分层,联合超声随访识别HVD。
  • 多普勒超声监测HVD有助于预测再干预或死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dysmetabolic profile has been associated with native aortic valve stenosis. However, there are limited data on the effects of an atherogenic milieu and its potential implications on the structural and hemodynamic deterioration of aortic bioprosthetic valves. OBJECTIVES: This prospective longitudinal study sought to determine the predictors and impact on outcomes of hemodynamic valve deterioration (HVD) of surgically implanted aortic bioprostheses. METHODS: A total of 137 patients with an aortic bioprosthesis implanted for a median time of 6.7 (interquartile range: 5.1 to 9.1) years prospectively underwent a first (baseline) assessment with complete Doppler echocardiography, quantitation of bioprosthesis leaflet calcification by multidetector computed tomography (CT), and a fasting blood sample to assess cardiometabolic risk profile. All patients underwent a second (follow-up) Doppler echocardiography examination at 3 (interquartile range: 2.9 to 3.3) years post-baseline visit. HVD was defined by an annualized change in mean transprosthetic gradient ≥3 mm Hg/year and/or worsening or transprosthetic regurgitation by ≥1/3 class. The primary endpoint was a nonhierarchical composite of death from any cause or aortic reintervention procedure (redo surgical valve replacement or transcatheter valve-in-valve implantation) for bioprosthesis failure. RESULTS: Thirty-four patients (25.6%) had leaflet calcification on baseline CT, and 18 patients (13.1%) developed an HVD between baseline and follow-up echocardiography. Fifty-two patients (38.0%) met the primary endpoint during subsequent follow-up after the second echocardiographic examination. Leaflet calcification (hazard ratio [HR]: 2.58; 95% confidence interval [CI]: 1.35 to 4.82; p = 0.005) and HVD (HR: 5.12; 95% CI: 2.57 to 9.71; p < 0.001) were independent predictors of the primary endpoint. Leaflet calcification, insulin resistance (homeostatic model assessment index ≥2.7), lipoprotein-associated phospholipase A2 activity (Lp-PLA2 per 0.1 nmol/min/ml increase), and high level of proprotein convertase subtilisin/kexin 9 (PCSK9) (≥305 ng/ml) were associated with the development of HVD after adjusting for age, sex, and time interval since aortic valve replacement. CONCLUSIONS: HVD identified by Doppler echocardiography is independently associated with a marked increase in the risk of valve reintervention or mortality in patients with a surgical aortic bioprosthesis. A dysmetabolic profile characterized by elevated plasma Lp-PLA2, PCSK9, and homeostatic model assessment index was associated with increased risk of HVD. The presence of leaflet calcification as detected by CT was a strong predictor of HVD, providing incremental risk-predictive capacity.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Salaun E, Mahjoub H, Dahou A, et al. Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves. J Am Coll Cardiol. 2018. PMID: 30012316. doi:10.1016/j.jacc.2018.04.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。